AbbVie Inc. $ABBV Stake Lessened by Everett Harris & Co. CA

Posted by Geri Gentry on Oct 30th, 2026

Everett Harris & Co. CA lessened its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 0.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 509,046 shares of the company’s stock after selling 3,495 shares during the quarter. AbbVie comprises about 1.6% of Everett Harris & Co. CA’s investment portfolio, making the stock its 13th biggest holding. Everett Harris & Co. CA’s holdings in AbbVie were worth $133,161,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. ERn Financial LLC raised its holdings in AbbVie by 5.6% during the third quarter. ERn Financial LLC now owns 1,545 shares of the company’s stock worth $404,000 after purchasing an additional 82 shares in the last quarter. Crew Capital Management Ltd boosted its stake in AbbVie by 1.1% during the 3rd quarter. Crew Capital Management Ltd now owns 8,648 shares of the company’s stock valued at $2,262,000 after purchasing an additional 97 shares in the last quarter. Financial Solutions Advisory Group Inc. boosted its stake in AbbVie by 4.9% during the 3rd quarter. Financial Solutions Advisory Group Inc. now owns 10,209 shares of the company’s stock valued at $2,914,000 after purchasing an additional 478 shares in the last quarter. Choreo LLC boosted its stake in AbbVie by 7.7% during the 3rd quarter. Choreo LLC now owns 113,422 shares of the company’s stock valued at $29,670,000 after purchasing an additional 8,102 shares in the last quarter. Finally, Argentarii LLC increased its position in shares of AbbVie by 2.0% during the 3rd quarter. Argentarii LLC now owns 4,375 shares of the company’s stock valued at $1,145,000 after purchasing an additional 84 shares during the period. Institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: QULIPTA delivered favorable Phase 3 results. AbbVie said its migraine-prevention treatment atogepant (QULIPTA) demonstrated superior efficacy and tolerability versus topiramate in the TEMPLE head-to-head study. The data could strengthen QULIPTA’s competitive position and support future growth. AbbVie’s QULIPTA Outperforms Topiramate in Phase 3 Migraine Prevention Study
Positive Sentiment: Analysts expect a better-than-expected third quarter. The preview points to continued momentum from immunology drugs Skyrizi and Rinvoq, which are increasingly important as AbbVie replaces lost Humira revenue. A strong report and maintained or improved guidance could provide a near-term catalyst. AbbVie Q3 Preview
Positive Sentiment: AbbVie filed for FDA review of etentamig. The multiple myeloma candidate is backed by a positive pivotal Phase 3 trial and could expand AbbVie’s oncology portfolio if approved. The monthly dosing schedule may also improve its commercial appeal. AbbVie Seeks FDA Approval for Etentamig
Neutral Sentiment: Early-stage pipeline activity continues. An updated Phase 1 study of ABBV-7828 signals ongoing investment in new medicines, but the program remains preliminary and is unlikely to materially affect near-term earnings. AbbVie’s ABBV-7828 Trial
Negative Sentiment: Patent-cliff concerns remain. Analysts continue to warn that Humira’s loss of exclusivity and future patent expirations could pressure revenue and earnings, placing greater importance on Skyrizi, Rinvoq, QULIPTA and the broader pipeline. AbbVie Still Strong Growth, but Patent Cliff Is Getting Closer

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Royal Bank Of Canada reissued an “outperform” rating and issued a $280.00 price objective on shares of AbbVie in a research note on Tuesday, October 13th. Leerink Partners raised their target price on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. raised their target price on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Rothschild & Co Redburn lifted their target price on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, Cantor Fitzgerald boosted their price target on shares of AbbVie from $285.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $279.86.

Read Our Latest Analysis on AbbVie

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is owned by insiders.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $289.85 on Friday. The stock has a market capitalization of $512.10 billion, a price-to-earnings ratio of 81.88, a PEG ratio of 1.31 and a beta of 0.24. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $292.67. The company has a 50 day moving average price of $268.69 and a 200 day moving average price of $236.86.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.97 earnings per share. On average, sell-side analysts expect that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

AbbVie Company Profile

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.